Terapia (Tx) Neoadiuvante del Carcinoma a Cellule di Merkel con l'Inibitore PD-1 Cemiplimab (NeoMatryx)
Terapia (Tx) Neoadiuvante del Carcinoma a Cellule di Merkel con l'Inibitore PD-1 Cemiplimab - Uno Studio di Fase II Randomizzato, in Doppio Cieco, Controllato con Placebo e Non Comparativo
The study is a randomized, double blind, placebo-controlled, non-comparative phase II trial that investigates the efficacy of neoadjuvant anti-PD-1 antibody Cemiplimab treatment in patients with clinical stage I or II Merkel cell carcinoma who have have undergone primary tumour excision and are pending sentinel lymph node biopsy.
Panoramica dello studio
Stato
Stato
Condizioni
Condizioni
Intervento / Trattamento
Intervento / Trattamento
Tipo di studio
Tipo di studio
Iscrizione (Stimato)
Iscrizione
Fase
Fase
- Fase 2
Contatti e Sedi
Contatto studio
Contatto studio
- Nome: Michelle Tez
- Email: tez.michelle@ikf-khnw.de
Backup dei contatti dello studio
- Nome: Ralf Gutzmer, Prof. Dr. med.
- Email: Ralf.Gutzmer@Muehlenkreiskliniken.de
Luoghi di studio
-
-
Baden-Wurttemberg
-
Heidelberg, Baden-Wurttemberg, Germania, 69120
- Reclutamento
- Nationales Centrum für Tumorerkrankungen
-
Contatto:
- Jessica Hassel, Prof. Dr.
-
Mannheim, Baden-Wurttemberg, Germania, 68161
- Reclutamento
- Universitätsklinikum Mannheim
-
Contatto:
- Jochen Utikal, Prof. Dr.
-
Tübingen, Baden-Wurttemberg, Germania, 72076
- Reclutamento
- Universitätsklinikum Tübingen
-
Contatto:
- Ulrike Leiter-Stöppke, Prof. Dr.
-
-
Bavaria
-
Regensburg, Bavaria, Germania, 93053
- Reclutamento
- Universitätsklinikum Regensburg
-
Contatto:
- Sebastian Haferkamp, Prof. Dr.
-
Würzburg, Bavaria, Germania, 97080
- Reclutamento
- Universitätsklinikum Würzburg
-
Contatto:
- Anja Gieserich, Dr.
-
-
Free and Hanseatic City of Hamburg
-
Hamburg, Free and Hanseatic City of Hamburg, Germania, 20246
- Reclutamento
- Universitätsklinikum Hamburg-Eppendorf
-
Contatto:
- Christoffer Gebhardt, Prof. Dr.
-
-
Hesse
-
Frankfurt am Main, Hesse, Germania, 60590
- Reclutamento
- Universitätsklinikum Frankfurt
-
Contatto:
- Bastian Schilling, Prof. Dr.
-
-
North Rhine-Westphalia
-
Bielefeld, North Rhine-Westphalia, Germania, 33647
- Reclutamento
- Klinikum Bielefeld
-
Contatto:
- Selma Ugurel, Prof. Dr.
-
Essen, North Rhine-Westphalia, Germania, 45147
- Reclutamento
- Universitätsklinikum Essen
-
Contatto:
- Dirk Schadendorf, Prof. Dr.
-
Minden, North Rhine-Westphalia, Germania, 32429
- Non ancora reclutamento
- Johannes Wesling Klinikum Minden
-
Contatto:
- Ralf Gutzmer, Prof. Dr.
-
-
Rhineland-Palatinate
-
Mainz, Rhineland-Palatinate, Germania, 55131
- Reclutamento
- Universitätsmedizin Mainz
-
Contatto:
- Stefan Grabbe, Prof. Dr.
-
-
Thuringia
-
Erfurt, Thuringia, Germania, 99089
- Reclutamento
- Helios Klinikum Erfurt
-
Contatto:
- Rudolph Herbst, Prof. Dr.
-
-
Criteri di partecipazione
Criteri di ammissibilità
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria
-
Patient has signed informed written consent.
-
Patients is 18 years and older at time of signing of written informed consent
-
Patient has diagnosis of Merkel cell carcinoma in clinical stage II, or in stage I with minimum diameter of 1 cm, with primary tumor already removed and a planned sentinel lymph nodes biopsy still pending.
-
Patient has ECOG performance status 0-2.
-
Patients has adequate laboratory parameters particularly for the blood count, renal and liver function parameters.
- Absolute number of neutrophils ≥ 1.5 x 109/L
- Platelets ≥ 75 x 109/L
- Hemoglobin ≥ 9 g/dL
- Total bilirubin ≤ 1.5 times the upper limit of normal (ULN) (patients with Gilbert´s Disease and total bilirubin up to 3x ULN may be eligible after approval from trial's medical expert)
- AST (SGOT) and ALT (SGPT) ≤ 3x ULN
- AP ≤ 2.5x ULN
- Serum creatinine ≤ 2x ULN or creatinine clearance ≥ 40 mL/min
-
Female patients of childbearing potential and male patients with female partners of childbearing potential must agree to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of Cemiplimab. Male patients must refrain from donating sperm during this same period. Male patients with a pregnant partner must agree to remain abstinent or to use a condom for the duration of the pregnancy.
-
Patient must be willing to allow translational work-up of tissue samples (PT, sentinel lymph node biopsy).
Exclusion criteria
-
Patient has prior sentinel lymph node removal for the current MCC.
-
Patients received prior treatment with immunotherapy (such as PD-1/PD-L1 or CTL4) or any other systemic anti-tumor (MCC) therapy (incl. investigational therapies)
-
Patient has active or a history of hematological neoplasms including chronic lymphocytic leukemia (CLL), irrespective if these require treatment or not.
-
Patient had prior organ transplantation including allogenic stem-cell transplantation.
-
Patient receives immunosuppressive concomitant medication, EXCEPT for the following:
i. Intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection).
ii. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent.
iii. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
-
Patient has known hypersensitivity to any component of the Cemiplimab formulation as well as a known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion protein.
-
Patient has active autoimmune or inflammatory disorders.
-
Patient has history of interstitial lung disease.
-
Patient has active infection requiring systemic therapy.
-
Patient has Active infection requiring systemic therapy, including uncontrolled HIV, HBV and HCV infection or diagnosis of immunodeficiency.
NOTE: Patients are eligible if:
- Patients have controlled HIV infection with CD4 counts is > 350 cells/μL and viral load is undetectable [HIV RNA PCR]. Patients with controlled HIV infection must be monitored per local standards during the trial.
- Patients positive for HBV surface antigen have controlled HBV infection receiving anti-viral therapy and with undetectable serum viral load [HBV DNA PCR]. Patients with controlled infection must undergo periodic monitoring of HBV DNA and p must remain on anti-viral therapy for at least 6 months after last dose of Cemiplimab.
- Patients positive for HCV antibody have controlled HCV infection with undetectable viral load [HCV RNA PCR].
-
Patent received vaccination with any live vaccine (e.g., intranasal flu vaccine) within 4 weeks before the first dose of Cemiplimab or planned vaccination with live vaccine during the trial
-
Female patients, who are pregnant or breast feeding or planning to become pregnant within and 6 months after the end of treatment. Female patients of childbearing potential must have a negative serum β-HCG pregnancy test result within 7 days prior to initiation of study treatment.
-
Patient has evidence of any other disease, neurologic or metabolic dysfunction, physical examination finding or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of any of the study medications, puts the patient at higher risk for treatment-related complications or may affect the interpretation of study results.
-
Patient has known substance abuse or other psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
-
Patient is legally incapacitated or has limited legal capacity
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Quadruplicare
Numero di armi
Armi e interventi
Gruppo di partecipanti / ArmGruppo di partecipanti / Arm |
Intervento / TrattamentoIntervento / Trattamento |
|---|---|
|
Sperimentale: Arm A (Cemiplimab)
2 cycles of Cemiplimab (350 mg, i.v., Q3W) followed by sentinel lymph node biopsy |
Patients will receive Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles
Altri nomi:
|
|
Comparatore placebo: Arm B (placebo)
2 cycles of placebo followed by sentinel lymph node biopsy |
Patients will receive NaCl 0.9% solution i.v. on day 1 of every 21 days cycle for 2 cycles. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Nodal micrometastases-free rate
Lasso di tempo: up to 36 months
|
rate of patients without nodal micrometastases after 2 cycles of treatment, determined by sentinel lymph node biopsy |
up to 36 months
|
Misure di risultato secondarie
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Recurrence-free survival
Lasso di tempo: up to 66 months
|
time from randomization until date of the first of the following events: MCC recurrence, and MCC-related death |
up to 66 months
|
|
Time to recurrence
Lasso di tempo: up to 66 months
|
defined as time from randomization until date of first MCC recurrence |
up to 66 months
|
|
Overall survival
Lasso di tempo: up to 66 months
|
time from randomization until date of death from any cause |
up to 66 months
|
|
Quality of life using FCRI-SF questionnaire
Lasso di tempo: up to 66 months
|
Quality of life determined using the FCRI-SF questionnaire |
up to 66 months
|
|
Safety (AEs and SAEs)
Lasso di tempo: up to 66 months
|
incidence, nature, causality, frequency, timing and severity of adverse events using NCI CTCAE 5 |
up to 66 months
|
|
Disease specific survival
Lasso di tempo: up to 66 months
|
time from randomization until date of MCC-related death |
up to 66 months
|
|
Quality of life using the mFACT-M questionnaire
Lasso di tempo: up to 66 months
|
Quality of life determined using the mFACT-M questionnaire |
up to 66 months
|
Altre misure di risultato
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Investigation of prognostic and predictive biomarkers to estimate the risk of lymph node metastases and signs of immune activation in the sentinel lymph nodes
Lasso di tempo: up to 66 months
|
Biosamples will be used to determine the correlation of identified biomarkers with clinical outcome, i.e., nodal metastases-free rate, RFS, OS |
up to 66 months
|
Collaboratori e investigatori
Sponsor
Sponsor
Collaboratori
Collaboratori
Investigatori
Investigatori
- Direttore dello studio: Salah Al-Batran, Prof. Dr., Institut für Klinische Krebsforschung IKF GmbH
- Investigatore principale: Ralf Gutzmer, Prof. Dr. med., Johannes Wesling Klinikum Minden
- Investigatore principale: Juergen C. Becker, Prof. Dr. Dr., Translational Skin Cancer Research University Duisburg-Essen, Germany
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Inizio studio
Completamento primario (Stimato)
Completamento primario
Completamento dello studio (Stimato)
Completamento dello studio
Date di iscrizione allo studio
Primo inviato
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Primo Inserito
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento pubblicato
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Infezioni
- Malattie virali
- Neoplasie per tipo istologico
- Neoplasie, ghiandolari ed epiteliali
- Adenocarcinoma
- Infezioni da virus del DNA
- Malattie della pelle
- Carcinoma
- Tumori neuroectodermici
- Neoplasie, cellule germinali ed embrionali
- Neoplasie, tessuto nervoso
- Tumori neuroendocrini
- Infezioni da virus tumorali
- Infezioni da poliomavirus
- Carcinoma, neuroendocrino
- Malattie della pelle e del tessuto connettivo
- Neoplasie cutanee
- Carcinoma, cellule di Merkel
- Cemiplimab
Altri numeri di identificazione dello studio
Altri numeri di identificazione dello studio
- NeoMatryx
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .